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ABSTRACT
Objective To determine adherence to recommended
surveillance intervals in clinical practice.
Design 2997 successive patients with a ﬁrst adenoma
diagnosis (57% male, mean age 59 years) from
10 hospitals, who underwent colonoscopy between
1998 and 2002, were identiﬁed via Pathologisch
Anatomisch Landelijk Geautomatiseerd Archief: Dutch
Pathology Registry. Their medical records were reviewed
until 1 December 2008. Time to and ﬁndings at ﬁrst
surveillance colonoscopy were assessed. A surveillance
colonoscopy occurring within ±3 months of a 1-year
recommended interval and ±6 months of a
recommended interval of 2 years or longer was
considered appropriate. The analysis was stratiﬁed by
period per change in guideline (before 2002: 2–3 years
for patients with 1 adenoma, annually otherwise; in
2002: 6 years for 1–2 adenomas, 3 years otherwise).
We also assessed differences in adenoma and colorectal
cancer recurrence rates by surveillance timing.
Results Surveillance was inappropriate in 76% and
89% of patients diagnosed before 2002 and in 2002,
respectively. Patients eligible under the pre-2002
guideline mainly received surveillance too late or were
absent (57% of cases). For patients eligible under the
2002 guideline surveillance occurred mainly too early
(48%). The rate of advanced neoplasia at surveillance
was higher in patients with delayed surveillance
compared with those with too early or appropriate timed
surveillance (8% vs 4–5%, p<0.01).
Conclusions There is much room for improving
surveillance practice. Less than 25% of patients with
adenoma receive appropriate surveillance. Such practice
seriously hampers the effectiveness and efﬁciency of
surveillance, as too early surveillance poses a
considerable burden on available resources while delayed
surveillance is associated with an increased rate of
advanced adenoma and especially colorectal cancer.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading
causes of cancer-related death in the Western
world.1 2 Individuals with adenomas are at
increased risk to develop CRC compared with the
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Signiﬁcance of this study
What is already known on this subject?
▸ A considerable proportion of colonoscopy use
concerns procedures for surveillance purposes.
This proportion will further increase with the
introduction of mass screening for colorectal
cancer (CRC).
▸ For optimal effectiveness of CRC prevention
and limitation of resource depletion, adherence
to postpolypectomy surveillance guidelines is
mandatory.
▸ Surveys show that gastroenterologists often
advise shorter surveillance intervals than
recommended by guidelines.
▸ No large studies have assessed adherence to
surveillance guidelines in clinical practice.
What are the new ﬁndings?
▸ In clinical practice, only a minority of patients
(11–24%) receives appropriate surveillance
according to guidelines. This is considerably
lower than previously estimated from surveys.
▸ Over 45% of patients receive too intense
surveillance compared with the 2002
guidelines.
▸ Compared with appropriate or too early
surveillance, delayed surveillance was associated
with a higher rate of advanced and non-
advanced neoplasia at surveillance colonoscopy.
▸ Poor penetration of the 2002 surveillance
guidelines within 1 year following
implementation illustrates the importance of
convincing evidence to support endorsement of
new guidelines by physicians.
How might it impact on clinical practice in
the foreseeable future?
▸ Physicians should realise that current adherence
to guidelines is inappropriate and that that can
seriously hamper effectiveness and efﬁciency of
surveillance.
▸ Speciﬁc interventions should be compared for their
effectiveness to improve guideline adherence.
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average population, even after the adenoma has been
removed.3–6 Patients with adenoma are therefore recommended
to undergo regular colonoscopy surveillance.7–10 Currently in
the USA about 15–25% of all colonoscopy procedures are being
performed for surveillance purposes,11 12 while in the
Netherlands estimates range from 13% to 40%.13 14 Previous
research indicated that adherence to postpolypectomy surveil-
lance guidelines is insufﬁcient.15–23 While too little surveillance
threatens the effectiveness of CRC prevention, too intensive sur-
veillance may lead to unnecessary harms and makes inefﬁcient
use of colonoscopy resources.
The introduction of mass screening for CRC combined with
aging of the population in many Western countries will consid-
erably increase the number of patients with adenoma in the
coming years, and thus the number of surveillance colonos-
copies required. The number of colonoscopies in the
Netherlands has increased signiﬁcantly from 117 000 in 2004
to 191 000 in 2009.24 An additional 66 000–99 000 colonos-
copies each year are expected with full implementation of CRC
screening (after a positive faecal immunochemical blood test
plus subsequent surveillance).13 25 26 The associated increase in
colonoscopy demand together with the limited colonoscopy
capacity in many countries27–30 emphasise the importance of
efﬁciency in surveillance practice and therefore adherence to
surveillance guidelines.
Previous studies regarding adherence to postpolypectomy sur-
veillance guidelines mainly consisted of surveys among gastroen-
terologists, in which the follow-up decision of the
gastroenterologist was compared with the guidelines’ recom-
mendation.16 18 20 31 However the gastroenterologist’s intention
immediately after the index colonoscopy is only one factor on
whether and when surveillance colonoscopy will take place.
Moreover these studies may be prone to bias because of medic-
ally desirable answers. Few studies assessed actual adherence to
postpolypectomy surveillance guidelines.19 23 32 These were
either relatively small single-centre studies19 32 33 or based on a
self-reported patient survey.23 In addition, the proportion of
patients not having surveillance at all was not always assessed.
We aimed to determine the extent of adherence to postpoly-
pectomy surveillance guidelines in community-based clinical
practice, in which we were also in the position to assess the
inﬂuence of a change in guideline on adherence rates.
METHODS
Patient selection
We used the nationwide registry of histopathology and cyto-
pathology in the Netherlands (Pathologisch Anatomisch
Landelijk Geautomatiseerd Archief, PALGA)34 to identify
patients with a ﬁrst adenoma diagnosis in the period from 1 June
1998 to 31 December 2002 in 10 hospitals (3 academic and 7
non-academic) throughout the Netherlands. This registry
includes a résumé of ﬁndings of all tissue materials (eg, polyps,
biopsies) that have been submitted at any pathology centre in the
Netherlands since 1991. Years of inclusion of patients with
adenoma per hospital depended on the availability of electronic
medical records. Patients with a ﬁrst adenoma diagnosis aged 40–
74 years were eligible for inclusion. Patients with any of the fol-
lowing criteria were excluded: (1) (suspected) hereditary CRC
syndromes, in particular Lynch syndrome (hereditary non-
polyposis colorectal carcinoma), familial adenomatous polyposis,
Peutz-Jeghers syndrome, juvenile polyposis or polyposis asso-
ciated with mutations in the MUTYH gene; (2) personal history
of CRC or CRC at index colonoscopy; (3) (previous) bowel
resections; (4) IBD; (5) acromegaly; (6) ureterosigmoidostomy;
and (7) recommended age of next surveillance exceeded the
recommended age to stop surveillance. Exclusion criteria 4 to 6
are associated with an increased CRC risk, and we have therefore
excluded patients with these conditions.
Data collection
After identiﬁcation of patients with a ﬁrst adenoma diagnosis via
the PALGA database, patients’ medical records, in particular
endoscopy and pathology reports, were reviewed in 10 hospitals
to collect information on patient characteristics, index and sur-
veillance colonoscopy (colonoscopy or sigmoidoscopy) including
corresponding adenoma characteristics, until 1 December 2008,
the end of the study. Index colonoscopy was deﬁned as colonos-
copy or sigmoidoscopy with ﬁrst adenoma diagnosis. We consid-
ered repeat colonoscopy examinations performed either within
6 months after index colonoscopy, or after surveillance colonos-
copy as one examination. In case of combining results from col-
onoscopies, the date of last colonoscopy with the fullest reach
including polypectomy was used. For all patients, date of index
colonoscopy, age and sex were collected. In patients without a
surveillance colonoscopy before 1 December 2008, we only col-
lected data on index colonoscopy characteristics and adenoma
ﬁndings in a randomly picked sample of 40% (433/1093) of
patients. In all patients with surveillance after adenoma detection
we collected data on colonoscopy characteristics and adenoma
ﬁndings, at index and surveillance colonoscopy.
This study was approved by the Institutional Review Board of
Erasmus MC University Medical Centre and all participating
centres.
Outcomes
We evaluated the time interval to ﬁrst surveillance colonoscopy as
our main outcome measure. Absence of surveillance was deﬁned
as not having received surveillance within 90 months or before the
end of the study period, whichever came ﬁrst. The deﬁnition of
appropriate surveillance was based on the active guideline. In the
Netherlands, from June 1998 to October 2001, patients with one
adenoma were recommended a 2–3 year surveillance interval;
patients with more than one adenoma a 1-year interval.35 36 In
October 2001, a revised guideline was published and implemented
from January 2002 onwards. It was communicated at a national
conference and through a report including a wallet sized card with
the summary of the guideline by the Dutch Institute for
Healthcare Improvement.37 The revised guideline recommended
patients with three or more adenomas to have surveillance after
3 years, and patients with fewer than three adenomas to return for
surveillance after 6 years. Surveillance colonoscopy could be
ceased after age 65 years for patients with cumulative one
adenoma at that age, and after age 75 years for patients with
cumulative two adenomas.10 The timing of surveillance colonos-
copy was arbitrarily considered appropriate if surveillance has
been performed within the range of ±3 months for the 1-year rec-
ommendation, and ±6 months for the 2–6 year recommendations.
The corresponding appropriate surveillance intervals are given in
table 1. We also assessed the yield of advanced adenoma (AA) and
non-AA at surveillance colonoscopy and relate this to the number
of adenomas at index colonoscopy and surveillance interval.
Statistical analysis
We used Kaplan-Meier (KM) analysis to estimate the probability
over time since polypectomy that a patient would have surveil-
lance colonoscopy. The analysis was stratiﬁed by two different
periods corresponding to the active guideline ( June 1998 to
2002, and from 2002 onwards), and by adenoma number at
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index colonoscopy: one, two, and three+ adenomas. Each
patient in the study cohort was followed from index colonos-
copy until the ﬁrst surveillance colonoscopy, or until censored.
Patients were censored (A) at reported time of death, (B) on 1
December 1 2008 or (C) 90 months after index colonoscopy,
whichever came ﬁrst. We assumed no loss to follow-up.
Differences in characteristics between groups were assessed by
the Mann-Whitney U test, Kruskal-Wallis test or χ2 test. The
log-rank test (Mantel-Cox) was used to compare KM curves. All
statistical analyses were conducted using the Statistical Package for
Social Sciences for Windows V.17.0 (SPSS, Chicago, Illinois, USA).
Two-sided p values <0.05 were considered statistically signiﬁcant.
Missing values
To perform the KM analysis stratiﬁed by active guideline and
adenoma number at index colonoscopy, we needed data on
adenoma number for all subjects. However, we only collected
data on adenoma ﬁndings for a subgroup of patients without
surveillance (n=433/1093). For missing values for adenoma
number (n=660) and gender (n=1) we used a statistical imput-
ation technique.38 Imputations were based on correlations with
patient characteristics (age and sex); hospital type (academic or
non-academic); year of index colonoscopy, reach and prepar-
ation of index colonoscopy; adenoma characteristics (number of
adenomas; presence of villous adenoma; presence of adenomas
sized ≥10 mm (as measured by the endoscopist or pathologist);
adenomas with high-grade dysplasia; and proximal adenomas);
and presence of a surveillance colonoscopy, using the
aregImpute function in R V.2.11 software (R foundation for stat-
istical computing, Vienna, Austria).
Subanalyses
To assess the inﬂuence of having hospitals in the data set
without observations over the whole index period ( June 1998–
2002), we compared the KM curves of surveillance timing from
ﬁve hospitals with data over the whole period with the other
hospitals.
Also, two subanalyses were performed regarding implementa-
tion issues. A change in guideline usually involves a transitional
phase in which anticipation (before) and implementation issues
(after) inﬂuence actual practice. Regarding the former issue,
endoscopists possibly anticipated the lengthening of the surveil-
lance intervals in upcoming guidelines. Also, because of the
change in the guideline in 2002, clinicians may have prolonged
surveillance intervals for patients with a ﬁrst adenoma diagnosis
in 2001 retroactively. We therefore considered the period from
October 2000 (1 year before guideline publication) until
December 2001 as the transitional phase between the two
guidelines. We compared the median surveillance intervals and
results of the KM analysis between the periods June 1998–
October 2000 and October 2000–December 2001.
Second, because it might take time to familiarise and comply
with a new guideline, we also compared median surveillance
intervals and the results of the KM analysis for the ﬁrst half of
2002 versus the second half of 2002.
Additionally, we compared KM curves of time to surveillance
colonoscopy between academic and non-academic hospitals and
between hospitals with or without an active follow-up system.
In general, gastroenterologists gave surveillance recommenda-
tions to their patients and informed the patients’ general practi-
tioner. In hospitals with an active follow-up system patients
were actively reminded to have surveillance colonoscopy by the
endoscopy centre. For all subanalyses we looked at patients with
one, two or three+ adenomas separately.
RESULTS
A total of 2997 patients with a ﬁrst adenoma diagnosis were
included in our study (ﬁgure 1). Their mean age was 58.6 (SD
9.0) years and 57.2% were male (table 2). Of all index endosco-
pies, 2691 (89.8%) were intended colonoscopies and 306
(10.2%) were sigmoidoscopies. In total, 2303 patients had a
ﬁrst adenoma diagnosis before 2002 and 694 patients in 2002.
Most patients with adenoma (70%) were seen in non-academic
hospitals. Of all patients with adenoma 11.6% had three or
more adenomas. The contribution to this study in the number
of patients per hospital varied from 84 to 565.
The study follow-up period considered in our analysis for
patients diagnosed before 2002 ranged between 83 months and
90 months. For the patients diagnosed in 2002 it was between
71 months and 82 months. Of the patients with surveillance col-
onoscopy, the median (25th–75th centile) intervals to ﬁrst sur-
veillance colonoscopy were 25 (13–40) months for patients with
their index colonoscopy before 2002 and 35 (14–48) months
for those with their index colonoscopy in 2002 (p<0.001).
Before 2002, median surveillance intervals were 27 (13–45)
months for those with one adenoma, 22 (12–37) months for
those with two adenomas and 16 (12–35) months for patients
with three+ adenomas (p<0.001). In 2002, these intervals
were 37 (20–50) months for those with one adenoma, 35 (13–
45) months for those with two adenomas and 24 (12–
37) months for patients with three+ adenomas (p<0.001).
Patients with an index colonoscopy in 2002 were seen after a
longer interval than those with an index colonoscopy before
2002 (ﬁgure 2A–C). Overall, 21% of patients with adenoma
received appropriate surveillance (table 3). The pre-2002 sur-
veillance guideline was better adhered to than the 2002 guide-
line (24% vs 11% appropriateness). In both periods, a higher
proportion of patients with three+ adenomas received appropri-
ate surveillance than patients with one and two adenomas
(before 2002: 30% vs 24% and 23%, and in 2002: 18% vs 9%
and 11%, respectively).
The overall yield of AA at surveillance was 5% and 7% for
patients in both index periods, respectively (table 4). The yield
of non-AA was 22% for both periods (see online supplementary
appendix 1). The yield of AA at surveillance was, in particular
in the index period before 2002, higher in patients with delayed
surveillance compared with those with too early or appropriate
timed surveillance (8% vs 3% and 4%, p<0.01). This also per-
tained to the yield of CRC (1.8% vs 0.2% and 0.4%, p<0.01).
Table 1 Recommended surveillance intervals and intervals considered appropriate in the presented analysis
Adenoma findings at index colonoscopy Surveillance interval recommendation Interval considered appropriate*
June 1998–2001 ≥2 adenomas 12 months (1 year) 9–15 months
1 adenoma 24–36 months (2–3 years) 18–42 months
Since 2002 ≥3 adenomas 36 months (3 years) 30–42 months
1 or 2 adenomas 72 months (6 years) 66–78 months
*Appropriate interval is ±3 months for a 1-year interval recommendation and ±6 months for longer interval recommendations.
1586 van Heijningen E-MB, et al. Gut 2015;64:1584–1592. doi:10.1136/gutjnl-2013-306453
Colon
group.bmj.com on November 23, 2017 - Published by http://gut.bmj.com/Downloaded from 
Subanalyses
Results of all subanalyses are presented in online supplementary
appendix 2. No differences were observed in surveillance
pattern when comparing ﬁve hospitals with data over the whole
index period (1998–2002) with those without.
Patients with an index colonoscopy in the phase immediately
preceding the change in guideline (October 2000–December
2001) had a signiﬁcantly longer median (25th–75th centile) sur-
veillance interval than patients with an index colonoscopy
between June 1998 and October 2000: 29 (14–44) months
versus 21 (12–39) months (p<0.001). However, KM curves for
these two periods were only signiﬁcantly different for patients
with one adenoma (p<0.001).
Median surveillance intervals were similar between patients
with an index colonoscopy in the ﬁrst half of 2002 versus those
in the second half of 2002 for patients with one, two or three+
adenomas (data not shown). Also, KM curves did not differ sig-
niﬁcantly, indicating no signiﬁcant implementation issues con-
cerning the new guideline, although the period might have been
too short.
When comparing surveillance pattern from academic versus
non-academic hospitals, a difference was observed for patients
with one or two adenomas with their index colonoscopy before
2002, with longer intervals and less follow-up in academic
centres. For hospitals with an active versus passive follow-up
system, a different surveillance pattern was observed in patients
with two or more adenomas in 2002, with longer intervals and
less follow-up in centres with an active follow-up system.
DISCUSSION
This study shows high proportions of inappropriate adherence to
the postpolypectomy surveillance guidelines that are in effect in
the Netherlands. This ﬁnding holds for both guideline periods
considered: before 2002, only 24% of patients received appro-
priately timed adenoma-surveillance; in 2002 only 11% did.
Overall, a third of the patients did not receive surveillance at all
by the end of the study period. The absence of surveillance in
such a large fraction of the patients is alarming, because advanced
neoplasia was found in 8% (of which a ﬁfth were CRCs) of those
with delayed surveillance, and in particular up to 17% in those
with three or more adenomas at index colonoscopy.
Before 2002, inappropriate surveillance was predominantly
too late or absent (together, 57% of patients), while in 2002,
when the recommended surveillance intervals were lengthened,
Figure 1 Identiﬁcation of the study
cohort and the subgroups.
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48% of the patients received surveillance too early. Appropriate
adherence to surveillance guidelines was somewhat higher for
patients with three or more adenomas than for patients with
fewer than three adenomas (overall, 26% vs 21%).
The fact that surveillance was mostly delayed before 2002 can
be expected when the recommended intervals are relatively
short (1 year and 2–3 years). This ﬁnding coincides with the
ﬁndings of two previous small single-centre studies from the
Netherlands and the UK.19 39 The 2002 change in recommen-
dations to 3 years for patients with three+ adenomas and
6 years for patients with one to two adenomas was associated
with a change in average practice towards longer surveillance
intervals. However, the increase in interval in actual practice
was smaller than the increase in the guideline-recommended
interval. As a result, the proportion of patients that received too
early surveillance increased from 19% before 2002 to 48% in
2002. This proportion was higher for patients with one to two
adenomas compared with those with three+ adenomas (50% vs
39% in 2002). The impact of too early surveillance on colonos-
copy demand will be largest in patients with one to two aden-
omas, since this group represents more than 80% of the current
patient population with adenoma.
The poor penetration of the 2002 guideline within 1 year fol-
lowing the implementation illustrates the importance of convin-
cing evidence to support endorsement of new guidelines by
community practice. The 2002 guideline was formulated when
only limited data were available and showed differences with
other international guidelines. It has also been shown that
gastroenterologist experienced dilemmas with the guideline,18
which may explain non-compliance. Patients assumed to be at
higher risk for other reasons than adenoma number may have
received earlier surveillance colonoscopy than recommended by
the guideline. This latter can also be an explanation why the
yield of AA was similar for patients with too early surveillance
compared with those having appropriately timed surveillance
(7% and 5%, respectively). Last year the Dutch guideline has
been updated and includes additional adenoma characteristics
(http://www.mdl.nl/uploads/240/1308/Richtlijn_Coloscopie_
Surveillance_deﬁnitief_2013.pdf). Although we combined index
colonoscopies within 6 months, some patients still did not have
sufﬁcient bowel preparation (165 of those with surveillance),
however it turned out not to be a reason for earlier surveillance.
Intervals were not different from patients with sufﬁcient bowel
preparation (data not shown).
Our ﬁndings that surveillance was too frequent in patients
whose recommended surveillance intervals were longer (ie, 3
and 6 years) are in line with self-reported surveillance intervals
in US and European surveys among gastroenterologists and/or
surgeons,16–18 20 22 and also with the few smaller studies that
assessed the appropriate timing of postpolypectomy surveillance
colonoscopy in clinical practice.32 40 In the latter, 46–54% of
the patients with surveillance received it too early.32 40 In our
study, the corresponding percentage was even higher: 76% (ie,
48% of 63% of the patients with surveillance).
Schoen et al23 reported that surveillance colonoscopy was too
early in 34% of patients with a low-risk adenoma proﬁle
(patients with one or two non-AAs). The larger proportion of
overuse among the low-risk group in our study (48%) may be
explained by the discrepancy in risk stratiﬁcation between the
guidelines in effect: whereas patients with one or two adenomas
and high-grade dysplasia, a (tubulo) villous aspect, or a size
≥10 mm are classiﬁed as high-risk patients according to the US
guideline and advised a 3-year surveillance interval,9 the Dutch
2002 guidelines classiﬁed these patients as ‘low-risk’ and recom-
mended a 6-year interval.10 Physicians in the Netherlands may
have shortened the intervals for these patients, considering them
to be at higher risk.18 On the other hand, we also found a consid-
erably greater overuse of surveillance among patients with a high-
risk adenoma proﬁle (39% in patients with ≥three adenomas)
than Schoen et al23 did (14–20% patients with ≥three non-AAs
or ≥one AA). In the USA, high-risk patients have been recom-
mended a 3-year interval since 1993. As a consequence, US phy-
sicians may be more familiar with the 3-year recommendation
than the Dutch physicians were in 2002. Generally, the propor-
tion of patients with too early surveillance tends to be higher
among low-risk patients than among higher-risk patients,23 32 39 41
which may again be inherent to the relatively longer recom-
mended surveillance interval itself or be related to a perceived
need for shorter surveillance by patients or their physicians.
An important ﬁnding in our study is that an estimated third
of patients do not receive surveillance colonoscopy after
adenoma detection in community practice. Schoen et al23
Table 2 Characteristics of the study population at index
colonoscopy (n=2997)
All patients (n=2997)
Characteristics of patients with adenoma
Male (n, %) 1713 (57.2)
Age (mean, SD) 58.6 (9.0)
Active guideline (n, %)
June 1998–2001 2303 (76.8)
2002 694 (23.2)
Hospital type (n, %)
Non-academic 2097 (70.0)
Academic 900 (30.0)
Geographical area (n, %)
High density population area 1641 (54.8)
Low density population area 1356 (45.2)
Active follow-up system (n, %)
No 1975 (65.9)
Yes 1022 (34.1)
Adenoma characteristics
No. of adenomas (mean, SD)* 1.5 (0.9)
No. patients with (n, %)
multiple (≥3) adenomas* 347 (11.6)
Any adenoma with size ≥10 mm†‡ 1127 (37.6)
Any adenoma with high-grade dysplasia† 368 (12.3)
Any villous adenoma† 150 (5.0)
Any proximal adenoma† 900 (30.0)
Index endoscopy characteristics
Intended sigmoidoscopy (n, %) 306 (10.2)
Reach endoscope (n, %)†
Complete colonoscopy§ 2538 (84.7)
Proximal colon 293 (9.8)
Distal colon 166 (5.5)
Bowel preparation (n, %)†
Good¶ 2723 (90.9)
Moderate 221 (7.4)
Insufficient 52 (1.7)
*Variable truncated to 5+ adenomas, and imputed for missing values.
†Weighted average (data from 433 patients without surveillance weighted to the
1093 patients without surveillance).
‡Size ≥10 mm either as reported by an endoscopist or a pathologist.
§58 missings assumed to have a complete colonoscopy (in 2337 (1904+433) patients
with data).
¶1598 missings assumed to have a good bowel preparation (in 2337 (1904+433)
patients with data).
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reported that approximately half of patients had not (yet)
received surveillance colonoscopy after 5 years. These data were
based on patient questionnaires and lacked actual assessment of
hospital records. Cooper et al42 found a similar proportion
using Medicare claims data. However, this population only
included subjects aged 70 years and above. Furthermore, as this
study was based on Medicare claims data, it implied that it used
endoscopy billing codes, in particular polypectomy, instead of
histological evaluation. As such, there was no veriﬁcation of
adenoma removal, and also lacked information on advanced
versus non-advanced histology. Appropriateness of adherence to
guidelines could thus not be assessed. Insight into the absence
of surveillance is important in the light of the 8% advanced
neoplasia (1.8% CRC, 6.6% AA) recurrence rate and 25%
non-AA recurrence rate in patients with delayed surveillance.
This shows that the observed delays are long enough for neopla-
sia to reoccur and/or progress, and corroborates the expectation
that there is a loss in effectiveness when patients do not have
timely or not at all have surveillance colonoscopies.
Our study is one of the few studies to have assessed the actual
use of postpolypectomy surveillance colonoscopy in clinical prac-
tice in a multicentre setting; and it is of considerable size. But two
limitations are noteworthy. First, we assumed no loss to follow-up.
We feel this is a reasonable assumption, because patient deaths
were well-reported in hospital databases (the observed death rate
closely matched the expected rate based on age and gender of the
population, data not shown) and we did not ﬁnd correspondence
in medical records on colonoscopies performed elsewhere. Finally,
the close link between patient, referring family physician, and hos-
pital in the Netherlands induce that the vast majority of patients in
the Netherlands regularly attend the same hospital for surveillance
and other purposes. Most importantly, we found our results to be
robust for this assumption: even if all patients without surveillance
would have died or had their surveillance colonoscopy in another
hospital with a similar timing as observed for the other patients,
still only 32% (21%/66%) would have received appropriate
surveillance.
Second, because of time constraints we collected information on
index adenoma number in a random sample of 40% (433/1093) of
the patients without surveillance colonoscopy after adenoma detec-
tion. We assume that this sample is representative. We statistically
imputed adenoma number for 660 patients. We expect any bias
due to misclassiﬁcation of patients according to number of aden-
omas (one, two or three+ adenomas) as a result of imputation to
be very small, and that it will not have affected adherence rates.
Our results show that postpolypectomy surveillance guidelines
are not being applied appropriately—a much larger proportion
than one would expect deviates from the recommendations.
Some non-compliance, especially delayed or absent surveillance,
should be expected for good reasons, notably comorbidity issues.
As far as we know there is no literature on comorbidity rates in
patients with adenoma, but it is unlikely that the presence of
comorbidity fully explains the observed lack of surveillance in
our study. Patients who receive adenoma-surveillance too early
represent unnecessary endoscopic procedures, harms and costs.
As the implementation of mass screening for CRC is expected to
(further) increase the demand for colonoscopies considerably, it
will become even more important to avoid unnecessary use of
resources, especially for low-risk patients. On the other side of
the spectrum of non-adherence, delayed or absent surveillance
represents loss of health beneﬁts.
Which interventions could improve adherence to surveillance
guidelines? Several interventions have been previously suggested.
One was to update the Dutch 2002 postpolypectomy surveillance
guideline towards less discrepancy with the endoscopist’s judg-
ment, and thereby improving physicians’ compliance. Other sug-
gestions include an active approach policy directed towards
patients and general practitioners to invite patients for a surveil-
lance colonoscopy,19 43 to disseminate summarised guidelines
Figure 2 (A) Kaplan-Meier probability curve for surveillance
colonoscopy use by month from index colonoscopy for patients with
one adenoma, stratiﬁed by active guideline. The shaded areas indicate
appropriate intervals around 2–3 years (<2002, n=1676) and 6 years
(2002, n=417). (B) Kaplan-Meier probability curve for surveillance
colonoscopy use by month from index colonoscopy for patients with
two adenomas, stratiﬁed by active guideline. The shaded areas indicate
appropriate intervals around 1 year (<2002, n=397) and 6 years (2002,
n=160). (C) Kaplan-Meier probability curve for surveillance colonoscopy
use by month from index colonoscopy for patients with three or more
adenomas, stratiﬁed by active guideline. The shaded areas indicate
appropriate intervals around 1 year (<2002, n=230) and 3 years
(2002, n=117).
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among professionals through the distribution of wallet-sized
cards (which nowadays can also be applications for mobile
devices), to place guideline charts near workstations, to reinforce
guidelines in regular continuous quality-improvement meetings44
and to supervise application of guidelines by a nurse coordin-
ator.45 46 It is also necessary to increase patients’ awareness in
terms of their adenoma ﬁndings and the need for surveillance,
including recommended surveillance interval.47 Implementation
studies are required to determine which of the interventions
work best. Monitoring postpolypectomy surveillance intervals
combined with efforts to encourage timely adherence should be a
mainstay in continuous quality improvement.
In conclusion, the vast majority of patients with adenoma in
community-based clinical practice (76–89%) did not receive
surveillance timed according to Dutch postpolypectomy surveil-
lance guidelines. The poor penetration of the 2002 guideline
within 1 year following the implementation, illustrates the
importance of convincing evidence to support endorsement of
new guidelines by community practice. Our results suggest that
there is considerable room for improving the effectiveness and
efﬁciency of surveillance practice, because too early surveillance
poses a considerable burden on available resources while
delayed surveillance is associated with an increased rate of AA
and especially CRC. Since adherence to guidelines is mandatory
for the effectiveness and cost-effectiveness of CRC prevention
(including CRC screening programs), measures should be taken
to improve adherence. Implementation studies are needed to
determine which of the potential interventions work best.
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Table 4 Yield of advanced adenoma (AA) at surveillance endoscopy according to number of adenomas at index colonoscopy and timing of
surveillance according to the guidelines (n=1904)
Period of index
colonoscopy
Recommended
interval (year)
AA (n/n total)
Too early Appropriate† Delayed Total
June 1998–2001
1 adenoma 2–3 3% (12/389) 3% (13/384) 7% (21/298)* 4% (46/1071)
2 adenomas 1 6% (1/16) 3% (3/90) 6% (10/159) 5% (14/265)
3+ adenomas 1 7% (1/14) 9% (6/68) 17% (15/89) 13% (22/171)
Overall 3% (14/419) 4% (22/542) 8% (46/546)** 5% (82/1507)
In 2002
1 adenoma 6 5% (9/193) 7% (2/28) 0% (0/3) 5% (11/224)
2 adenomas 6 9% (8/86) 8% (1/12) – 9% (9/98)
3+ adenomas 3 16% (7/44) 0% (0/20) 9% (1/11) 11% (8/75)
Overall 7% (24/323) 5% (3/60) 7% (1/14) 7% (28/397)
Total 5% (38/742) 4% (25/602) 8% (47/560)** 6% (110/1904)
AA includes adenomas with size of 10 mm or larger at pathology or endoscopy, villous histology or high-grade dysplasia, including CRC.
In total 14 CRCs were found at first surveillance colonoscopy (Before 2002: 1 CRC in those with too early surveillance, 1 CRC in those with appropriately timed surveillance and 10 CRCs
in those with delayed surveillance. In 2002: 2 CRCs in those with too early surveillance).
*Significant at level p<0.05; **Significant at level p<0.01.
†Appropriate interval, before 2002: 1 year ±3 months, 2–3 years ±6 months; and in 2002: 3 years or 6-years ±6 months.
CRC, colorectal cancer.
Table 3 Timing of surveillance colonoscopy relative to recommended intervals according to guideline in effect (by period) and adenoma
patient group, Kaplan-Meier analysis
Period of index
colonoscopy
Recommended
interval (year) Too early (%) Appropriate* (%)
Delayed or
no surveillance (%)
No
surveillance† (%)
June 1998–2001
1 adenoma (n=1676) 2–3 24 24 53 35
2 adenomas (n=397) 1 4 23 73 32
3+ adenomas (n=230) 1 6 30 63 22
Overall (n=2303) 19 24 57 33
In 2002
1 adenoma (n=417) 6 47 9 44 40
2 adenomas (n=160) 6 57 11 33 33
3+ adenomas (n=117) 3 39 18 43 33
Overall (n=694) 48 11 41 37
Overall, all patients (n=2997) 25 21 53 34
Due to rounding row percentages may not add up to 100%.
*Appropriate interval, before 2002: 1-year plus or minus 3 months, 2–3 years plus or minus 6 months; and in 2002: 3- or 6-years plus or minus 6 months.
†by the end of the study (1 December 2008) or within 90 months, whichever came first.
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